BioSpace News Archive

FSD Pharma Inc., a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to announce the appointment of Dr. Sanjiv Chopra to its board of directors.

Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the “Company”), a western Canadian-based life sciences company,

CNS Pharmaceuticals, Inc. announced the pricing of its “reasonable best efforts” public offering with participation from healthcare-focused institutional investors and certain officers and directors of the Company for the purchase and sale of 13,333,334 shares of common stock at a purchase price of $0.30 per share.

HUTCHMED Limited announces that the marketing approval of ELUNATE® by the Pharmacy and Poisons Board of Hong Kong for the treatment of adult patients with previously treated metastatic colorectal cancer.

Showcasing its longstanding partnership with the United Arab Emirates Emirates Health Services, Children’s Hospital of Philadelphia will exhibit thought-leading clinical research in the EHS booth at the Arab Health 2024 Exhibition and Congress, taking place this week in Dubai.

Daiichi Sankyo and AstraZeneca’s supplemental Biologics License Application for ENHERTU® has been accepted and granted Priority Review in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive solid tumors who have received prior treatment or who have no satisfactory alternative treatment options.

On December 12, 2022, Novozymes and Chr. Hansen entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies.

AntiCancer Inc. announced it has just received US Patent 11,871,731 that describes a method to increase the rate of establishment of patient tumors in mice to close to 100%.

Vera Therapeutics, Inc. announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $200.0 million of shares of its Class A common stock.

Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced that Oculis’ management will be attending and presenting at the following upcoming investor conferences: